[1] Henchal EA, Putnak JR.The dengue viruses[J]. Clin Microbiol Rev, 1990, 3(4):376-379. [2] Whitehoru J, Farrar J.Dengue[J]. Br Med Boll, 2010, 95:161-173. [3] Guirakhoo F, Pugachev K, Zhang Z, et al.Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates[J]. J Virol, 2004, 78(9):4761-4775. [4] Inoue S, Morita K, Matias RR, et al.Distribution of three arbovirus antibodies among monkeys (Macaca fascicularis) in the Philippines[J]. J Med Primatol, 2003, 32(2):89-94. [5] Angsubhakorn S, Moe JB, Marchette NJ, et al.Neurovirulence detection of dengue virus using rhesus and cynomolgus monkeys[J]. J Virol methods, 1987, 10:13-24. [6] Martina BE, Koraka P, Osterhaus AD.Dengue virus pathogenesis: an integrated view[J]. Clin Microbiol Rev, 2009, 22(4):564-581. [7] Taweechaisupapong S, Sriurairatana S, Angsubhakorn S, et al.In vivo and in vitro studies on the morphological change in the monkey epidermal Langerhans cells following exposure to dengue 2 (16681) virus[J]. Southeast Asian J Trop Med Public Health, 1996, 27(4):664-672. [8] Halstead SB, Shotwell H, Casals J.Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection[J]. J Infect Dis, 1973, 128(1):7-14. [9] Halstead SB, Shotwell H, Casals J.Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis, 1973, 128(1):15-22. [10] Marchette NJ, Halstead SB, Falkler WJ.Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections[J]. J Infect Dis, 1973, 128(1):23-30. [11] Fagbami AH, Monath TP, Fabiyi A.Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans[J]. J Trans R Soc Trop Med Hyg, 1977, 71(1):60-65. [12] García G, Alvarez M, Santana E, et al.Detection of lymphoproliferative response in monkeys innoculated with dengue 4 virus[J]. Rev Cubana Med Trop, 2003, 55(1):27-29. [13] Angsubhakorn S, Yoksan S, Pradermwong A, et al.Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis[J]. Am J Trop Med Hyg, 1994, 31:65-70. [14] Guy B, Barban V, Mantel N, et al.Evaluation of interferences between dengue vaccine serotypes in a monkey model[J]. Am J Trop Med Hyg, 2009, 80(2):302-311. [15] Osorio JE, Brewoo JN, Silengo SJ, et al.Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques[J]. Am J Trop Med Hyg, 2011, 84(6):978-987. [16] Ito M, Katakai Y, Ono F, et al.Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes[J]. Arch Virol, 2011, 156(6):1073-1077. [17] Onlamoon N, Noisakran S, Hsiao HM, et al.Dengue virus-induced hemorrhage in a nonhuman primate model[J]. Blood, 2010, 115(9):1823-1834. [18] Koraka P, Benton S, Amerongen G, et al.Efficacy of a live attenuated tetravalent candidate dengue vaccine in naďve and previously infected cynomolgus macaques[J]. Vaccine, 2007, (29):5409-5416. [19] Durbin AP, Whitehead SS.Dengue vaccine candidates in development[J]. Curr Top Microbiol Immunol, 2010; 338:129-143. [20] Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine [J]. Hum Vaccin, 2010, 16; 6(9). [Epub ahead of print] [21] Bernardo L, Izquierdo A, Prado I.Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2[J]. Clin Vaccine Immunol, 2008, 15(3):439-446. [22] Rosen L.The Emperor s New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever[J]. Am J Trop Med Hyg, 1977, 26(3):337-343. [23] Capeding RZ, Luna IA, Bomasang E, et al.Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines[J]. Vaccine, 2011, 29(22):3863-3872. |